{"entity":{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","aka":[],"tldr":"Designed the second-generation CAR with a CD28 costimulatory domain that made CAR-T therapy work.","summary":"Michel Sadelain's laboratory at MSKCC created the CD19-targeted second-generation chimeric antigen receptor with a CD28 signalling domain, the design underlying axicabtagene ciloleucel and brexucabtagene autoleucel, and showed that costimulation was the key to making engineered T cells persist and kill. He led the first CD19 CAR-T trials in adult ALL with Renier Brentjens and pioneered CRISPR-targeted CAR insertion into the TRAC locus. He moved to Columbia in 2024.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sadelain%20M%5BAuthor%5D%20chimeric%20antigen%20receptor"}],"tags":["cell-therapy","car-t","engineering"],"related":[],"cancers":["all-leukemia","dlbcl"],"sections":[],"technologies":["car-t","in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["columbia-hicc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-1-axi-cel-nejm-2017"],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Director, Columbia Initiative in Cell Engineering and Therapy, Columbia University Irving Medical Center","institutionId":"columbia-hicc","specialisms":["CAR T-cell engineering","Gene therapy","Synthetic immunology","Cell therapy manufacturing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sadelain%20M%5BAuthor%5D%20chimeric%20antigen%20receptor"}],"papers":[{"title":"The basic principles of chimeric antigen receptor design","journal":"Cancer Discovery","year":2013,"doi":"10.1158/2159-8290.CD-13-0148"},{"title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","journal":"Science Translational Medicine","year":2013,"doi":"10.1126/scitranslmed.3005930"},{"title":"Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection","journal":"Nature","year":2017,"doi":"10.1038/nature21405"},{"title":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1707447","doi":"10.1056/NEJMoa1707447"}],"orcid":"0000-0002-9031-8025"},"route":"/people/michel-sadelain/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"institution":[{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/"}],"paper":[{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/"}],"journal":[{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/"}]}}